Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

Amplia Therapeutics has today announced that the first patient in the Phase 2a portion of the ACCENT trial has been dosed.

The completion of Phase 1b late last year identified a safe and well-tolerated dose of narmafotinib, paving the way to commence the next stage of the trial. The Phase 2a stage is designed to assess efficacy of narmafotinib, in combination with standard-of-care chemotherapy, in first-line pancreatic cancer patients.

The trial is being conducted at six trial sites open in Melbourne, Sydney and Brisbane, with five additional sites in Korea.

The trial will initially enrol 26 patients, with an interim analysis of efficacy to be conducted in mid-2024.

Amplia CEO and MD, Dr Chris Burns commented:

“Initiation of the Phase 2a stage of the trial is a significant milestone for Amplia. We are excited to be moving ahead with the next stage of the ACCENT trial with a safe and well-tolerated dose of narmafotinib. The trial in advanced pancreatic patients will determine whether narmafotinib, in combination with gemcitabine and Abraxane, provides improved efficacy for the treatment of this devastating cancer. Patients and clinicians are desperate for improved treatment options given the current five-year survival is only 12%.”

Click link below to read the full ASX Release.

First patient dosed in phase 2a ACCENT trial